Fax: (011) 852-2648-7097
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
Article first published online: 16 DEC 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 16, pages 3984–3992, 15 August 2012
How to Cite
Chan, S. L., Mo, F. K. F., Wong, C. S. C., Chan, C. M. L., Leung, L. K. S., Hui, E. P., Ma, B. B., Chan, A. T. C., Mok, T. S. K. and Yeo, W. (2012), A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer, 118: 3984–3992. doi: 10.1002/cncr.26726
- Issue published online: 3 AUG 2012
- Article first published online: 16 DEC 2011
- Manuscript Accepted: 26 OCT 2011
- Manuscript Revised: 25 OCT 2011
- Manuscript Received: 30 AUG 2011
- liver neoplasms;
- neoplasm staging;
- biologic markers
The level of circulating interleukin 10 (IL-10) is elevated in a proportion of patients with hepatocellular carcinoma (HCC). The objective of the current study was to evaluate the prognostic significance of serum the IL-10 level in patients with unresectable HCC.
Patients with unresectable HCC who provided serum at the time of diagnosis were enrolled prospectively in the study. The level of circulating IL-10 in serum samples was determined by enzyme-linked immunosorbent assay. The association of the IL-10 level with overall survival was evaluated in relation to sociodemographics, liver function, hepatitis B viral load, and tumor staging.
In total, 222 patients were recruited; of these, 82.4% were positive for hepatitis B virus surface antigen, and 65.8% had Barcelona Clinic Liver Cancer stage C disease. The mean log IL-10 level was 1.1 pg/mL, and 146 patients had an IL-10 level >1 pg/mL (high IL-10 group). The high IL-10 group had worse overall survival than the low IL-10 group (5.0 months vs 14.9 months; hazard ratio, 2.192; P < .0001). The IL-10 level was associated with worse hepatic function and with a high alanine transaminase (ALT) level. The IL-10 level remained an independent prognostic factor (hazard ratio, 1.824; P = .0005) after adjustment for sociodemographics, tumor staging, treatment, Child-Pugh stage, and ALT level. The IL-10 level also subdivided patients into 2 populations with distinct survival (10.2 months vs 3.5 months; P = .0027).
The serum IL-10 level was identified as an independent prognostic factor for unresectable HCC. The current findings suggested that an elevated IL-10 level may be related to hepatic injury caused by cirrhotic processes rather than tumor load. The authors concluded that the IL-10 level offers additional prognostic value to the existing tumor staging systems. Cancer 2012. © 2011 American Cancer Society.